cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Seelos Therapeutics Inc
19 own
18 watching
Current Price
$0.2
$0
(-2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
6.38M
52-Week High
52-Week High
254.39999
52-Week Low
52-Week Low
0.18170
Average Volume
Average Volume
0.43M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization6.38M
icon52-Week High254.39999
icon52-Week Low0.18170
iconAverage Volume0.43M
iconDividend Yield--
iconP/E Ratio--
What does the Seelos Therapeutics Inc do?
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Read More
How much money does Seelos Therapeutics Inc make?
News & Events about Seelos Therapeutics Inc.
PR Newswire
1 year ago
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting PR Newswire NEW YORK, May 5, 2023...
PR Newswire
1 year ago
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock PR Newswire NEW YORK, March 10, 2023 NEW YORK, March 10, 2023 /PRNewswire...
PR Newswire
1 year ago
Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit PR Newswire NEW YORK, Feb. 10, 2023...
PR Newswire
1 year ago
Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event PR Newswire NEW YORK, Dec. 22, 2022 NEW YORK, Dec. 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq...
PR Newswire
1 year ago
Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022 Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022 PR Newswire NEW YORK, Nov. 23, 2022 NEW YORK, Nov. 23, 2022 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Seelos Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Seelos Therapeutics Inc shares?
plus_minus_icon
How can I buy Seelos Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Seelos Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Seelos Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Seelos Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Seelos Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Seelos Therapeutics Inc?
plus_minus_icon
What percentage is Seelos Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Seelos Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.2
$0
(-2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$4.05
$-0.12 (-2.88 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$13.77
$-0.02 (-0.15 %)
Passage Bio Inc
Passage Bio Inc
$0.78
$0.01 (0.88 %)
I-Mab
I-Mab
$1.07
$-0.02 (-1.83 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$4.05
$-0.12 (-2.88 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$13.77
$-0.02 (-0.15 %)
Passage Bio Inc
Passage Bio Inc
$0.78
$0.01 (0.88 %)
I-Mab
I-Mab
$1.07
$-0.02 (-1.83 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00